Product Datasheet  
WEE1 (Phospho-Ser642) Antibody  
Catalog Number: 11706  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Rabbit
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot#: P30291;
    NCBI Gene#: 7465;
    NCBI Protein#: NP_003381.1.
  • Form of Antibody：  
  • Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Storage：  
  • Store at -20˚C/1 year
  • Immunogen：  
  • Peptide sequence around phosphorylation site of Serine 642(S-V-S(p)-L-T) derived from Human WEE1.
  • reactivity：  
  • Hu Ms Rt
  • appl_detail：  

  • Western blotting: 1:500~1:1000

  • other_names：  
  • WEE1A; WEE1hu; kinase WEE1;
  • Purification：  
  • Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
  • Specificity：  
  • The antibody detects endogenous levels of WEE1 only when phosphorylated at serine 642.
  • Applications：  
  • WB
  • Background：  

  • Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.

    Watanabe N., EMBO J. 14:1878-1891(1995).
    Cichutek A., Cytogenet. Cell Genet. 93:277-283(2001).
    Igarashi M., Nature 353:80-83(1991)




 
© Signalway Biotechnology All Rights Reserved.